Ipamorelin + CJC-1295: The Athlete's GH Stack, Examined

The ipamorelin + CJC-1295 combination is the most recommended "GH stack" in peptide forums and at grey-market clinics. The pitch is tidy: pair a peptide that mimics ghrelin with one that mimics GHRH, hit the pituitary from two angles at once, and trigger a bigger, more "natural" growth-hormone pulse than either does alone. The biochemistry behind that pitch is real. The part that gets skipped is whether any of it translates into the muscle, leanness, or recovery that athletes actually buy it for.

The honest headline, stated first so nothing below is misread: **the ipamorelin + CJC-1295 stack does reliably raise growth hormone and IGF-1 in humans, but there is no randomized controlled trial showing the stack improves body composition, strength, or athletic performance in healthy people.** Both peptides are unapproved research chemicals, they are used off-label, they are banned in tested sport, and the grey-market supply most people buy carries real quality risk. Keep that frame for every promising mechanism that follows.

What Each Peptide Actually Is

The two peptides in this stack work through two different receptors, which is exactly why they are combined.

**Ipamorelin** is a growth-hormone secretagogue (GHS) — a ghrelin mimetic. It binds the ghrelin receptor (GHS-R) on the pituitary and stimulates a growth-hormone pulse. When it was first described, ipamorelin was notable for being the first *selective* GHS: in the original pharmacology, it released growth hormone with potency comparable to older secretagogues but, unlike them, did not meaningfully raise cortisol, prolactin, or ACTH¹. That selectivity — a clean GH pulse without the stress-hormone spillover — is the entire reason ipamorelin became the forum-favorite ghrelin-side peptide.

**CJC-1295** is a different molecule entirely: a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor, not the ghrelin receptor. Its defining feature is duration. The version studied in humans was engineered to bind albumin in the bloodstream so it is cleared slowly, producing a prolonged elevation of GH and IGF-1 from a single dose rather than a brief spike². (That albumin-binding "drug affinity complex" design — the "DAC" you see in product names — is a real, documented modification, and it is precisely what anti-doping labs developed assays to detect³.) A short-acting version without the albumin tag, often sold as "CJC-1295 no-DAC" or modified GRF(1-29), produces a shorter pulse instead.

So the stack is GHRH-analog (CJC-1295) plus ghrelin-mimetic (ipamorelin). For the broader physiology of how these GH peptides relate to recovery, see our pillar on GH peptides and recovery.

The Stack Rationale — and Where It Holds Up

The theoretical case for combining them is genuinely reasonable, and it is worth stating fairly before taking it apart.

GH release is governed by two opposing signals: GHRH, which switches it on, and somatostatin, which switches it off. The two receptors targeted here sit at different points in that system. A GHRH analog (CJC-1295) pushes harder on the "on" switch and keeps it pushed; a ghrelin mimetic (ipamorelin) acts through a separate pathway that also amplifies GH secretion and can blunt somatostatin's braking effect. In principle, hitting both at once produces a larger, more physiologic GH pulse than either alone — a real synergy at the level of pituitary signaling.

And the downstream biomarker effect is not in doubt. CJC-1295 alone has been shown in healthy adults to raise both GH and IGF-1 for days after a single injection². Growth-hormone secretagogues as a class reliably raise serum IGF-1 in humans — that has been documented even for ipamorelin's oral cousins and in men treated with secretagogues clinically⁵. So if your goal is simply to move the GH and IGF-1 numbers on a lab panel, this stack does that. The mechanism works.

The problem is that moving those numbers is not the outcome anyone actually cares about.

The Outcome Gap — Stated Plainly

Here is the part the marketing skips. **No randomized controlled trial has shown that the ipamorelin + CJC-1295 stack — or either peptide alone — improves body composition, strength, or athletic performance in healthy people.** Raising GH and IGF-1 is a surrogate marker, not a result. The two are not the same thing, and the GH-secretagogue field has a long, sobering track record of the marker rising while the outcome does not.

The most informative human data come from MK-677 (ibutamoren), an oral ghrelin mimetic in the same secretagogue class as ipamorelin and far better studied. In a randomized, placebo-controlled trial in healthy older adults, MK-677 reliably raised GH and IGF-1 and increased *fat-free mass*⁴. That sounds like a win — until you read what it did not do: it did not improve strength or function, and the increase in lean mass was not matched by the performance gains the secretagogue story promises⁴. An earlier study of the same drug even found the body-fat picture inconsistent with the hormone changes⁸. In other words, when a secretagogue's effects *were* measured rigorously and over time, the headline biomarker moved but the things athletes care about largely did not. There is no reason to assume an injectable ipamorelin/CJC-1295 stack — which has never been put through a comparable trial — does better.

Ipamorelin's own most rigorous human test makes the point from another direction. The one large randomized controlled trial of ipamorelin in people was not a performance study at all; it tested the peptide for postoperative ileus (sluggish gut after bowel surgery), on the strength of its ghrelin-like gut-motility effects shown in rodents⁶⁷. That trial **failed its primary endpoint**⁶. It is a useful reminder that ipamorelin has been formally studied in humans — just not for muscle or recovery, and when it was studied properly, it did not deliver. The body-composition and performance claims attached to it rest on mechanism and anecdote, not on a trial that measured them.

This is the same evidence trap that defines the rest of the category. Our review of BPC-157 for recovery and our evidence-first pillar on peptides for athletic recovery walk through the same pattern: a plausible mechanism, real biomarker movement, and a missing human outcome trial.

"Before and After": What People Are Actually Seeing

Search "CJC-1295 ipamorelin before and after" and you will find transformation photos and glowing logs. It is worth being precise about what those do and do not show.

A peptide that raises GH and, especially, that drives fluid retention can produce visible short-term changes — a fuller, sometimes puffier look, modest scale-weight shifts, the feeling of better sleep and recovery (GH secretagogues genuinely affect slow-wave sleep). None of that is evidence of the lean-mass-and-fat-loss recomposition the photos imply. Anecdotes cannot separate the peptide from the training, the diet, the water retention, the lighting, or the placebo effect that accompanies starting any new protocol. That is the entire reason controlled trials exist — and for this stack, they have not been done. A "before and after" is a testimonial, not data.

The Anti-Doping Reality

For any drug-tested athlete, the evidence debate is moot — this stack ends a career.

Both peptides are prohibited under the World Anti-Doping Agency Prohibited List. Growth-hormone secretagogues and GHRH analogs — the exact mechanisms of ipamorelin and CJC-1295 — fall under category **S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)**, which is banned at all times, in and out of competition. Anti-doping science treats them as a priority target: laboratories have specifically developed mass-spectrometry methods to detect GHRH analogs like CJC-1295³ and to screen for low-molecular-weight peptide drugs in athlete samples⁹. The U.S. Anti-Doping Agency lists peptide hormones and growth factors of this kind as prohibited and warns athletes directly against "research chemical" peptides¹⁰. A positive test is an anti-doping rule violation. We cover the broader compliance picture in our guide to whether GH peptides are safe and legal.

The Grey-Market Quality Problem

Neither ipamorelin nor CJC-1295 is an FDA-approved drug. The FDA has moved peptides of this kind off the list of substances that pharmacies may freely compound for human use, citing limited safety data and the difficulty of controlling peptide purity¹¹. The practical result is that virtually all of this stack is sold "for research use only" by grey-market vendors.

That introduces a risk independent of the peptides themselves: you cannot verify what is in the vial. Independent testing of research-chemical peptides has repeatedly found identity, purity, and dosing inconsistencies, and unapproved injectables add contamination and sterility risk on top of that. So even setting aside the missing efficacy evidence and the doping ban, you are left injecting an unregulated product of unknown contents.

Bottom Line

The ipamorelin + CJC-1295 stack has a real and internally coherent mechanism: a ghrelin mimetic and a long-acting GHRH analog that, together, reliably raise growth hormone and IGF-1 in humans. What it does not have is the thing that actually matters for a person deciding whether to use it: **a single human trial showing it improves body composition, strength, or performance.** The best-studied drug in this class raised the biomarker but not function; ipamorelin's one rigorous human trial was for a gut condition and failed. Layered on top of that evidence gap are three hard facts — both peptides are unapproved, both are WADA-banned in tested sport, and the grey-market supply is unreliable.

The honest position is not "this stack is proven" and not "it does nothing." It is this: the pituitary synergy is real, the biomarker bump is real, and the proven athletic benefit is absent. Until trials that measure outcomes exist, treat any confident "this stack recomped me" claim as a testimonial, not evidence. For where these peptides sit against the rest of the category — and which providers offer them with real oversight versus none — see our evidence-ranked guide to the best recovery peptides.